


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Recently Viewed
EXAS
Exact Sciences
ALEC
Alector
FL
Foot Locker
CCLD
CareCloud
PROP
Prairie Operating Co.
Most Trending
+11.78%
-6.36%
+3.34%
+6.85%
EXAS
Exact Sciences
$102.34
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
EXAS Price Performance
$101.56 (+0.77%)
$66.98 (+52.79%)
$53.81 (+90.19%)
$50.59 (+102.29%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
EXAS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
EXAS Street Sentiment is unimpressive and have negative views on the near-term outlook
EXAS has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Recent Upgrades and Downgrades
STRONG BUY
Date
Action
Rating
Firm
Nov 12, 2025
Reiterate
Overweight
Piper Sandler
Nov 06, 2025
Reiterate
Overweight
Wells Fargo
Nov 05, 2025
Reiterate
Buy
Benchmark
Nov 05, 2025
Reiterate
Buy
Guggenheim
Nov 05, 2025
Reiterate
Buy
Stifel
EXAS
Exact Sciences
102.34
+0.04%
ALEC
Alector
1.89
-1.05%
FL
Foot Locker
0.97
-2.02%
CCLD
CareCloud
2.71
-2.17%
PROP
Prairie Operating Co.
1.83
-1.61%
What is EXAS current stock price?
What are EXAS stock strengths?
What is EXAS Risk Level?
What is EXAS market cap and volume?
What is EXAS current Stock IQ?
Should I buy EXAS stock right now?
Is EXAS a Strong Buy right now?
What does a 'Strong Buy' rating mean for EXAS?
What does a 'Strong Sell' rating mean for EXAS?
What factors influence EXAS's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Recently Viewed
EXAS
Exact Sciences
ALEC
Alector
FL
Foot Locker
CCLD
CareCloud
PROP
Prairie Operating Co.
Most Trending
+11.78%
-6.36%
+3.34%
+6.85%
EXAS
Exact Sciences
Current Price
$102.34
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market
Recently Viewed
EXAS
Exact Sciences
102.34
+0.04%
ALEC
Alector
1.89
-1.05%
FL
Foot Locker
0.97
-2.02%
CCLD
CareCloud
2.71
-2.17%
PROP
Prairie Operating Co.
1.83
-1.61%

EXAS Price Performance
$101.56 (+0.77%)
$66.98 (+52.79%)
$53.81 (+90.19%)
$50.59 (+102.29%)
EXAS Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
EXAS Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
EXAS Street Sentiment is unimpressive and have negative views on the near-term outlook
EXAS has Fair risk level
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
Overall Wall Street Rating
STRONG BUY
Nov 12, 2025
Reiterate
Overweight
Piper Sandler
Nov 06, 2025
Reiterate
Overweight
Wells Fargo
Nov 05, 2025
Reiterate
Buy
Benchmark
Nov 05, 2025
Reiterate
Buy
Guggenheim
Nov 05, 2025
Reiterate
Buy
Stifel
Nov 05, 2025
Reiterate
Buy
TD Cowen
Nov 05, 2025
Reiterate
Outperform
Baird
Nov 05, 2025
Reiterate
Overweight
Barclays
EXAS Stock IQ
EXAS Latest Analysis
Exact Sciences Corp. (EXAS) Rose Following the Acquisition Announcement.
Tue Jan 27, 2026
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues Issues 2026 Revenue Guidance and Amends Earnout Terms with Exact Sciences. MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues Issues 2026 Revenue Guidance and Amends Earnout Terms with Exact Sciences
Mon Jan 12, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
EXAS Stock trends
EXAS Stock performance
EXAS Stock analysis
EXAS investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.